ReviewCurrent opinion in nephrology and hypertension2016
Nicotinamide and phosphate homeostasis in chronic kidney disease.
Review in Current opinion in nephrology and hypertension, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.Journal of the American Society of Nephrology : JASN · 2019Trial
- Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD 3-5 Stages.Kidney medicine · 2026Review
- Association of dietary niacin intake with all-cause mortality in chronic kidney disease: A retrospective cohort study of NHANES.PloS one · 2025Article
- Identification of serum biomarkers for chronic kidney disease using serum metabolomics.Renal failure · 2024Article
- Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor.International journal of nephrology and renovascular disease · 2024Review
- Understudied Hyperphosphatemia (Chronic Kidney Disease) Treatment Targets and New Biological Approaches.Medicina (Kaunas, Lithuania) · 2023Review
- Association between Vitamin Intake and Chronic Kidney Disease According to a Variant Located Upstream of theNutrients · 2022Article
- Past, Present, and Future of Phosphate Management.Kidney international reports · 2022Review
- Review
- Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.Current opinion in nephrology and hypertension · 2020Review
- Drug-Induced Hypophosphatemia: Current Insights.Drug safety · 2020Review
- Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.Metabolomics : Official journal of the Metabolomic Society · 2019Review
- Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.Journal of the American Society of Nephrology : JASN · 2019Article
- Intestinal phosphate absorption: The paracellular pathway predominates?Experimental biology and medicine (Maywood, N.J.) · 2019Article
- The role of SLC34A2 in intestinal phosphate absorption and phosphate homeostasis.Pflugers Archiv : European journal of physiology · 2019Review
- Substrates and inhibitors of phosphate transporters: from experimental tools to pathophysiological relevance.Pflugers Archiv : European journal of physiology · 2019Review
- A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?Drugs · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewHigher serum phosphate concentration is a central driver of the chronic kidney disease (CKD) mineral bone disorder (MBD). Although phosphate binders are commonly used to lower phosphate, they are minimally effective in CKD. Nicotinamide (vitamin B3) decreases intestinal phosphate transport in animals. Its efficacy and safety in CKD is uncertain. RECENT
findingsWe review data differentiating nicotinamide from nicotinic acid (niacin) and compare the metabolism and side-effect profile of each. Several recent studies have tested the safety and efficacy of nicotinamide in patients with CKD and the general population. Available data on efficacy and safety, gaps in knowledge, and ongoing studies to address them are described. SUMMARY: Nicotinamide is a novel potential tool to treat hyperphosphatemia in patients with CKD, but additional data on safety and efficacy are required before widespread clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.